安罗替尼联合IP方案治疗进展/复发小细胞肺癌临床研究
Clinical Observation of Anlotinib Combined with IP Regimen in the Treatment of Progressive/Recurrent Small Cell Lung Cancer
王磊 1徐淑娜 1田甜 1韩蕃颉1
作者信息
- 1. 山东第一医科大学附属人民医院,山东 济南 271199
- 折叠
摘要
目的 探讨安罗替尼联合IP方案(伊立替康+顺铂)治疗进展/复发小细胞肺癌(SCLC)的临床效果及其作用机制.方法 选取医院 2019 年 6 月至 2021 年 6 月收治的进展/复发SCLC患者 97 例,按随机数字表法分为对照组(48 例)和观察组(49 例),两组患者均予IP方案治疗,观察组患者加服盐酸安罗替尼胶囊.两组均以 28d为 1 个周期,连续治疗 2 个周期,随访 20 个月.结果 观察组患者的疾病控制率显著高于对照组(P<0.05);观察组患者治疗后的血清癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)、细胞角蛋白19 片段(Cyfra21-1)水平及肿瘤代谢体积(MTV)、血容量(BV)、血流量(BF)均显著低于对照组(P<0.05);观察组患者中位无进展生存期(PFS)显著长于对照组(7.5个月比5.5个月,P<0.05);两组患者的不同等级不良反应发生率、生存率均无显著差异(P>0.05).结论 安罗替尼联合IP方案治疗进展/复发SCLC,可降低患者的肿瘤负荷,延长PFS,机制可能与调节肿瘤标志物和改善血流灌注指标有关.
Abstract
Objective To investigate the clinical efficacy and mechanism of anlotinib combined with IP regimen(irinotecan + cisplatin)in the treatment of progressive/recurrent small cell lung cancer(SCLC).Methods A total of 97 patients with progressive/recurrent SCLC admitted to the hospital from June 2019 to June 2021 were selected and divided into the control group(48 cases)and the observation group(49 cases)by the random number table method.The patients in the two groups were treated with IP regimen,on this basis,the patients in the observation group were treated with Anlotinib Hydrochloride Capsules orally.Both groups were treated continuously for two cycles with 28 d as one cycle and followed up for 20 months.Results The disease control rate(DCR)in the observation group was significantly higher than that in the control group(P<0.05).After treatment,the serum carcinoembryonic antigen(CEA),neuron-specific enolase(NSE)and cytokeratin 19 fragment(Cyfra21-1)levels,metabolic tumor volume(MTV),blood volume(BV)and blood flow(BF)in the observation group were significantly lower than those in the control group(P<0.05).The median progression-free survival(PFS)in the observation group was significantly longer than that in the control group(7.5 months vs.5.5 months,P<0.05).There was no significant difference in the incidence of adverse reactions of different levels and survival rate between the two groups(P>0.05).Conclusion Anlotinib combined with IP regimen in the treatment of progressive/recurrent SCLC can reduce the tumor burden and prolong the PFS of patients.The mechanism may be related to the regulation of tumor markers and improvment of blood perfusion-related indexes.
关键词
安罗替尼/小细胞肺癌/复发/进展/肿瘤负荷/肿瘤标志物/无进展生存期Key words
anlotinib/small cell lung cancer/recurrence/progression/tumor burden/tumor marker/progression-free survival引用本文复制引用
基金项目
山东省优秀中青年科学家科研奖励基金(BS2020SW1011)
出版年
2024
国家科技期刊平台
NSTL
万方数据